TechnicianNetherlands Cancer Institute, Biotherapeutics Unit, Amsterdam, The Netherlands, Netherlands
61: Surgical considerations for tumor-infiltrating lymphocyte (TIL) therapy in melanoma: results from a randomized phase 3 trial.
Thursday, March 21, 20242:07pm – 2:17pm ET